High-Grade Glioma - Pipeline Review, H2 2015 Is Released High-Grade Glioma - Pipeline Review, H2 2015 Summary Global Markets Direct s, High-Grade Glioma Pipeline Review, H2 2015 , provides an overview of the High-Grade Glioma s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for High-Grade Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High-Grade Glioma and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of High-Grade Glioma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in the therapeutics development for High-Grade Glioma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the High-Grade Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the High-Grade Glioma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for High-Grade Glioma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding High-Grade Glioma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business
1
potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline with TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173382/high-gradeglioma-pipeline-review-h2-2015
Browse
To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173382/high-grade-glioma-pipeline-review-h2-2015 Table of Contents
Introduction 8 Global Markets Direct Report Coverage 8 High-Grade Glioma Overview 9 Therapeutics Development 10 Pipeline Products for High-Grade Glioma - Overview 10 Pipeline Products for High-Grade Glioma - Comparative Analysis 11 High-Grade Glioma - Therapeutics under Development by Companies 12 High-Grade Glioma - Therapeutics under Investigation by Universities/Institutes 14 High-Grade Glioma - Pipeline Products Glance 15 Clinical Stage Products 15 Early Stage Products 16 High-Grade Glioma - Products under Development by Companies 17 High-Grade Glioma - Products under Investigation by Universities/Institutes 18 High-Grade Glioma - Companies Involved in Therapeutics Development 19 AngioChem Inc. 19 Arog Pharmaceuticals, Inc. 20 Bayer AG 21 Boehringer Ingelheim GmbH 22 Cavion LLC 23 Kinex Pharmaceuticals, LLC 24 2
Merrimack Pharmaceuticals, Inc. 25 Millennium Pharmaceuticals, Inc. 26 Nektar Therapeutics 27 Novartis AG 28 Oncolytics Biotech Inc. 29 Sanofi 30 Stemline Therapeutics, Inc. 31 Targepeutics, Inc. 32 Tocagen Inc. 33 Virttu Biologics Limited 34 High-Grade Glioma - Therapeutics Assessment 35 Assessment by Monotherapy Products 35 Assessment by Combination Products 36 Assessment by Target 37 Assessment by Mechanism of Action 39 Assessment by Route of Administration 41 Assessment by Molecule Type 43 Drug Profiles 45 (dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 alisertib - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 crenolanib besylate - Drug Profile 51 3
Product Description 51 Mechanism of Action 51 R&D Progress 51 Dendritic Cell Therapy for Gliomas - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Dendritic Cell Therapy for Oncology - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 dianhydrogalactitol - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 etirinotecan pegol - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 flucytosine + TBio-01 - Drug Profile 61 Product Description 61 Mechanism of Action 61
4
R&D Progress 61 GB-13 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 Gene Therapy for High-Grade Glioma and Liver Transplantation - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 HSV-1716 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 irinotecan hydrochloride - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 irinotecan hydrochloride + TBio-02 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 KX-02 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 mibefradil dihydrochloride - Drug Profile 74 Product Description 74 5
Mechanism of Action 74 R&D Progress 74 nintedanib - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 paclitaxel trevatide - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 pelareorep - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 plerixafor - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 SL-701 - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 sorafenib tosylate - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92
6
Toca-Gamma - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 Toca-RNAi - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 vocimagene amiretrorepvec + flucytosine ER - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 High-Grade Glioma - Recent Pipeline Updates 100 High-Grade Glioma - Dormant Projects 153 High-Grade Glioma - Discontinued Products 154 High-Grade Glioma - Product Development Milestones 155 Featured News & Press Releases 155 Jun 01, 2015: Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 155 May 28, 2015: Cavion to Present Clinical Trial Data at ASCO 156 May 31, 2014: Positive Data from Phase 2 Trial of NKTR-102 in Patients with Avastin?-Refractory HighGrade Glioma Presented at 50th ASCO Meeting 156 Appendix 158 Methodology 158 Coverage 158 Secondary Research 158 Primary Research 158 Expert Panel Validation 158 7
Contact Us 158 Disclaimer 159
Read More http://www.idatainsights.com/reports-landing-page.php?id=173382/high-grade-gliomapipeline-review-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects
8
9